Olema Pharmaceuticals, Inc. (OLMA)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 43,902 | |||
| General and administrative | 3,962 | |||
| Total operating expenses | 47,864 | |||
| Loss from operations | -47,864 | |||
| Other income (loss) | 38 | |||
| Interest income | 4,042 | |||
| Total other income | 4,080 | |||
| Net loss | -43,784 | |||
| Net loss per share, basic (in dollars per share) | -0.51 | |||
| Net loss per share, diluted (in dollars per share) | -0.51 | |||
| Weighted average shares used to compute net loss per share, basic (in shares) | 85,497,426 | |||
| Weighted average shares used to compute net loss per share, diluted (in shares) | 85,497,426 | |||